Global Interleukin 17A Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Interleukin 17A market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Interleukin 17A is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Interleukin 17A include Abeome Corporation, Affibody AB, Cell Medica Limited, Orega Biotech SAS, AbbVie Inc, Eli Lilly and Company, Merck KGaA, Novartis AG and Johnson & Johnson, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Interleukin 17A, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Interleukin 17A, also provides the sales of main regions and countries. Of the upcoming market potential for Interleukin 17A, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Interleukin 17A sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Interleukin 17A market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Interleukin 17A sales, projected growth trends, production technology, application and end-user industry.


Interleukin 17A Segment by Company

Abeome Corporation
Affibody AB
Cell Medica Limited
Orega Biotech SAS
AbbVie Inc
Eli Lilly and Company
Merck KGaA
Novartis AG
Johnson & Johnson

Interleukin 17A Segment by Type

DLX-2882
CNTO-6785
ABY-035
Others

Interleukin 17A Segment by Application

Kidney Cancer
Chronic Pain
Liver Cancer
Others

Interleukin 17A Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 17A market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin 17A and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 17A.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin 17A market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Interleukin 17A manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Interleukin 17A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Interleukin 17A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Interleukin 17A Market Size, 2020 VS 2024 VS 2031
1.3 Global Interleukin 17A Market Size Estimates and Forecasts (2020-2031)
1.4 Global Interleukin 17A Sales Estimates and Forecasts (2020-2031)
1.5 Global Interleukin 17A Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Interleukin 17A Market Dynamics
2.1 Interleukin 17A Industry Trends
2.2 Interleukin 17A Industry Drivers
2.3 Interleukin 17A Industry Opportunities and Challenges
2.4 Interleukin 17A Industry Restraints
3 Interleukin 17A Market by Manufacturers
3.1 Global Interleukin 17A Revenue by Manufacturers (2020-2025)
3.2 Global Interleukin 17A Sales by Manufacturers (2020-2025)
3.3 Global Interleukin 17A Average Sales Price by Manufacturers (2020-2025)
3.4 Global Interleukin 17A Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Interleukin 17A Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Interleukin 17A Manufacturers, Product Type & Application
3.7 Global Interleukin 17A Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Interleukin 17A Market CR5 and HHI
3.8.2 Global Top 5 and 10 Interleukin 17A Players Market Share by Revenue in 2024
3.8.3 2024 Interleukin 17A Tier 1, Tier 2, and Tier 3
4 Interleukin 17A Market by Type
4.1 Interleukin 17A Type Introduction
4.1.1 DLX-2882
4.1.2 CNTO-6785
4.1.3 ABY-035
4.1.4 Others
4.2 Global Interleukin 17A Sales by Type
4.2.1 Global Interleukin 17A Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Interleukin 17A Sales by Type (2020-2031)
4.2.3 Global Interleukin 17A Sales Market Share by Type (2020-2031)
4.3 Global Interleukin 17A Revenue by Type
4.3.1 Global Interleukin 17A Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Interleukin 17A Revenue by Type (2020-2031)
4.3.3 Global Interleukin 17A Revenue Market Share by Type (2020-2031)
5 Interleukin 17A Market by Application
5.1 Interleukin 17A Application Introduction
5.1.1 Kidney Cancer
5.1.2 Chronic Pain
5.1.3 Liver Cancer
5.1.4 Others
5.2 Global Interleukin 17A Sales by Application
5.2.1 Global Interleukin 17A Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Interleukin 17A Sales by Application (2020-2031)
5.2.3 Global Interleukin 17A Sales Market Share by Application (2020-2031)
5.3 Global Interleukin 17A Revenue by Application
5.3.1 Global Interleukin 17A Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Interleukin 17A Revenue by Application (2020-2031)
5.3.3 Global Interleukin 17A Revenue Market Share by Application (2020-2031)
6 Global Interleukin 17A Sales by Region
6.1 Global Interleukin 17A Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Interleukin 17A Sales by Region (2020-2031)
6.2.1 Global Interleukin 17A Sales by Region (2020-2025)
6.2.2 Global Interleukin 17A Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Interleukin 17A Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Interleukin 17A Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Interleukin 17A Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Interleukin 17A Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Interleukin 17A Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Interleukin 17A Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Interleukin 17A Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Interleukin 17A Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Interleukin 17A Revenue by Region
7.1 Global Interleukin 17A Revenue by Region
7.1.1 Global Interleukin 17A Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Interleukin 17A Revenue by Region (2020-2025)
7.1.3 Global Interleukin 17A Revenue by Region (2026-2031)
7.1.4 Global Interleukin 17A Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Interleukin 17A Revenue (2020-2031)
7.2.2 North America Interleukin 17A Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Interleukin 17A Revenue (2020-2031)
7.3.2 Europe Interleukin 17A Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Interleukin 17A Revenue (2020-2031)
7.4.2 Asia-Pacific Interleukin 17A Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Interleukin 17A Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Interleukin 17A Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Abeome Corporation
8.1.1 Abeome Corporation Comapny Information
8.1.2 Abeome Corporation Business Overview
8.1.3 Abeome Corporation Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Abeome Corporation Interleukin 17A Product Portfolio
8.1.5 Abeome Corporation Recent Developments
8.2 Affibody AB
8.2.1 Affibody AB Comapny Information
8.2.2 Affibody AB Business Overview
8.2.3 Affibody AB Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Affibody AB Interleukin 17A Product Portfolio
8.2.5 Affibody AB Recent Developments
8.3 Cell Medica Limited
8.3.1 Cell Medica Limited Comapny Information
8.3.2 Cell Medica Limited Business Overview
8.3.3 Cell Medica Limited Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Cell Medica Limited Interleukin 17A Product Portfolio
8.3.5 Cell Medica Limited Recent Developments
8.4 Orega Biotech SAS
8.4.1 Orega Biotech SAS Comapny Information
8.4.2 Orega Biotech SAS Business Overview
8.4.3 Orega Biotech SAS Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Orega Biotech SAS Interleukin 17A Product Portfolio
8.4.5 Orega Biotech SAS Recent Developments
8.5 AbbVie Inc
8.5.1 AbbVie Inc Comapny Information
8.5.2 AbbVie Inc Business Overview
8.5.3 AbbVie Inc Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 AbbVie Inc Interleukin 17A Product Portfolio
8.5.5 AbbVie Inc Recent Developments
8.6 Eli Lilly and Company
8.6.1 Eli Lilly and Company Comapny Information
8.6.2 Eli Lilly and Company Business Overview
8.6.3 Eli Lilly and Company Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Eli Lilly and Company Interleukin 17A Product Portfolio
8.6.5 Eli Lilly and Company Recent Developments
8.7 Merck KGaA
8.7.1 Merck KGaA Comapny Information
8.7.2 Merck KGaA Business Overview
8.7.3 Merck KGaA Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Merck KGaA Interleukin 17A Product Portfolio
8.7.5 Merck KGaA Recent Developments
8.8 Novartis AG
8.8.1 Novartis AG Comapny Information
8.8.2 Novartis AG Business Overview
8.8.3 Novartis AG Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Novartis AG Interleukin 17A Product Portfolio
8.8.5 Novartis AG Recent Developments
8.9 Johnson & Johnson
8.9.1 Johnson & Johnson Comapny Information
8.9.2 Johnson & Johnson Business Overview
8.9.3 Johnson & Johnson Interleukin 17A Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Johnson & Johnson Interleukin 17A Product Portfolio
8.9.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Interleukin 17A Value Chain Analysis
9.1.1 Interleukin 17A Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Interleukin 17A Production Mode & Process
9.2 Interleukin 17A Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Interleukin 17A Distributors
9.2.3 Interleukin 17A Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings